Table of Content

1. Research Methodology


2. US Transdermal Patch Market Outlook
2.1 Approved Transdermal Patches Insight
2.2 Current Market Scenario
2.3 Favorable Market Growth Inhibitors
2.4 Clinical & Commercialization Challenges
2.5 Future Marketing Opportunities


3. Branded vs Generic Transdermal Patches Comparison


4. Transdermal Patch Clinical & Market Trends By Indication
4.1 Brain, Neurological & Psychotic Disorders
4.2 Hormone Modulators
4.2.1 Hormone Replacement Therapies (HRT)
4.2.2 Contraception
4.3 Diabetes
4.4 Vaccine
4.5 Substance Use Disorders
4.6 Cardiovascular Diseases


5. US Transdermal Patch Clinical Pipeline Overview
5.1 By Company
5.2 By Drug Class
5.3 By Indication
5.4 By Phase
5.5 By Priority Status



6. Cardiovascular Diseases Transdermal Patch - US Market Availability, Dosage & Price Analysis
6.1 Clonidine Transdermal Patch
6.2 Nitroglycerin Transdermal Patch


7. Opioid Drug Containing Transdermal Patches - US Market Availability, Dosage & Price Analysis
7.1 Fentanyl Transdermal Patch
7.2 Buprenorphine Transdermal Patch


8. Neurological Disorders Transdermal Patch - US Market Availability, Dosage & Price Analysis
8.1 Selegiline Transdermal Patch
8.2 Rivastigmine Transdermal Patch
8.3 Methylphenidate Transdermal Patch
8.4 Asenapine Transdermal Patch
8.5 Rotigotine Transdermal Patch (Neupro) sales
8.6 Donepezil Transdermal Patch
8.7 Dextroamphetamine Transdermal Patch


9. Hormonal Therapy Transdermal Patch - US Market Availability, Dosage & Price Analysis
9.1 Estradiol Transdermal Patch
9.2 Testosterone Transdermal Patch (Androderm)


10. Transdermal Patches for Other Conditions - US Market Availability, Dosage & Price Analysis
10.1 Nicotine Transdermal Patch
10.2 Oxybutynin Transdermal Patch
10.3 Granisetron Transdermal Patch (Sancuso)


11. US Transdermal Patch Clinical Trials Insight By Company, Indication & Phase
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-II
11.5 Phase-III
11.6 Preregistration
11.7 Registered


12. US Commercially Available Transdermal Patches Clinical Insight by Indication


13. Competitive Landscape
13.1 AbbVie
13.2 AFYX Therapeutics
13.3 Agile Therapeutics
13.4 Bayer HealthCare Pharmaceuticals
13.5 Corsair Pharma
13.6 DBV Technologies
13.7 Hisamitsu Pharmaceutical
13.8 IBSA
13.9 Privo Technologies
13.10 Psilera
13.11 Starton Therapeutics
13.12 Teikoku Pharma USA
13.13 Teikoku Seiyaku
13.14 UCB
13.15 Vaxess Technologiess
13.16 Verndari



List of Tables

Table 2-1: US – Currently Available Branded Transdermal Patches
Table 2-2: Features Required in Transdermal Patches
Table 3-1: Comparison of Features of Branded & Generic Patches
Table 7-1: Butrans – Initial Dose Calculation using Previous Opioid (Morphine) Dosage
Table 8-1: Daytrana - Recommended Titration Schedule for ADHD Treatment